Victor Sandor
Director/Board Member bij MERUS N.V.
Vermogen: 261 969 $ op 31-03-2024
Actieve functies van Victor Sandor
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
MERUS N.V. | Director/Board Member | 12-06-2019 | - |
Independent Dir/Board Member | 12-06-2019 | - | |
ADC THERAPEUTICS SA | Director/Board Member | 27-04-2020 | - |
Independent Dir/Board Member | 27-04-2020 | - | |
PRELUDE THERAPEUTICS INCORPORATED | Director/Board Member | 01-05-2020 | - |
Independent Dir/Board Member | - | - | |
KYMERA THERAPEUTICS, INC. | Director/Board Member | 03-11-2022 | - |
Independent Dir/Board Member | 03-11-2022 | - | |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Director/Board Member | 01-07-2019 | - |
Loopbaan van Victor Sandor
Eerdere bekende functies van Victor Sandor
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
INCYTE CORPORATION | Chief Tech/Sci/R&D Officer | 01-01-2010 | 01-09-2019 |
ARRAY TECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 22-09-2014 | 01-08-2019 |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Corporate Officer/Principal | 01-02-2010 | 01-09-2014 |
Opleiding van Victor Sandor
McGill University | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 7 |
Canada | 2 |
Nederland | 2 |
Operationeel
Director/Board Member | 5 |
Independent Dir/Board Member | 4 |
Chief Tech/Sci/R&D Officer | 2 |
Sectoraal
Health Technology | 9 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 5 |
---|---|
INCYTE CORPORATION | Health Technology |
MERUS N.V. | Health Technology |
ADC THERAPEUTICS SA | Health Technology |
PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
KYMERA THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Array BioPharma, Inc.
Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Health Technology |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Health Technology |
- Beurs
- Insiders
- Victor Sandor
- Ervaring